Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.910
+0.050 (1.30%)
Mar 9, 2026, 3:31 PM EDT - Market open
Grace Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Market Capitalization | 61 | 31 | 32 | 21 | 54 | 120 | |
| Market Cap Growth | 75.88% | -2.84% | 56.90% | -62.03% | -55.00% | 250.73% | |
| Enterprise Value | 41 | 20 | 7 | -10 | 8 | 92 | |
| Last Close Price | 3.86 | 2.28 | 3.42 | 2.76 | 7.32 | 28.80 | |
| PS Ratio | - | - | - | - | - | 612.61 | |
| PB Ratio | 0.92 | 0.47 | 0.52 | 0.30 | 0.50 | 2.16 | |
| P/TBV Ratio | 3.82 | 1.81 | 2.58 | 1.10 | 2.12 | 2.16 | |
| EV/Sales Ratio | - | - | - | - | - | 470.71 | |
| Debt / Equity Ratio | - | - | - | 0.01 | 0.00 | 0.00 | |
| Net Debt / Equity Ratio | -0.29 | -0.33 | -0.37 | -0.40 | -0.40 | -1.09 | |
| Net Debt / EBITDA Ratio | 1.66 | 1.33 | 2.04 | 1.52 | 3.87 | 6.19 | |
| Net Debt / FCF Ratio | 1.84 | 1.49 | 1.86 | 1.72 | 2.52 | 4.22 | |
| Asset Turnover | - | - | - | - | - | 0.01 | |
| Quick Ratio | 14.56 | 11.53 | 14.09 | 8.41 | 13.56 | 38.80 | |
| Current Ratio | 14.96 | 11.77 | 14.26 | 8.59 | 13.89 | 39.50 | |
| Return on Equity (ROE) | -10.22% | -14.91% | -19.82% | -48.15% | -11.98% | -57.33% | |
| Return on Assets (ROA) | -10.84% | -14.35% | -9.25% | -10.96% | -7.94% | -15.70% | |
| Return on Capital Employed (ROCE) | -16.70% | -23.80% | -15.70% | -24.00% | -9.70% | -17.60% | |
| Earnings Yield | -10.01% | -30.59% | -39.92% | -206.80% | -18.17% | -16.39% | |
| FCF Yield | -16.96% | -47.65% | -38.38% | -77.64% | -31.90% | -11.98% | |
| Buyback Yield / Dilution | -36.09% | -26.85% | -28.16% | -21.09% | -148.46% | -40.25% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.